142 related articles for article (PubMed ID: 38286976)
21. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
22. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Chen J; Bi G; Wu F; Qin X
Pediatr Res; 2023 May; 93(6):1491-1498. PubMed ID: 36071237
[TBL] [Abstract][Full Text] [Related]
23. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
24. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
25. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
27. Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya.
Obayo A; Ngunga M; Shah J; Sokwala A; Barasa A
Cardiovasc J Afr; 2022 Jul-Aug 23; 33(4):186-192. PubMed ID: 35118489
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulation prescribing patterns in patients with cancer.
Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
[TBL] [Abstract][Full Text] [Related]
29. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of oral anticoagulants in extreme weights.
Chin-Hon J; Davenport L; Huang J; Akerman M; Hindenburg A
Thromb Res; 2023 Nov; 231():1-6. PubMed ID: 37738772
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
Jo J; Diaz M; Horbinski C; Mackman N; Bagley S; Broekman M; Rak J; Perry J; Pabinger I; Key NS; Schiff D
Neuro Oncol; 2023 Aug; 25(8):1381-1394. PubMed ID: 37100086
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
Yassine D; Brown EN; Putney D; Fasoranti O
J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102
[TBL] [Abstract][Full Text] [Related]
34. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
Bistervels IM; Bavalia R; Gebel M; Lensing AWA; Middeldorp S; Prins MH; Coppens M
J Thromb Haemost; 2022 Jun; 20(6):1376-1384. PubMed ID: 35253983
[TBL] [Abstract][Full Text] [Related]
35. Management of venous thromboembolism in patients with glioma.
Al Megren M; De Wit C; Al Qahtani M; Le Gal G; Carrier M
Thromb Res; 2017 Aug; 156():105-108. PubMed ID: 28624717
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic anticoagulation for venous thromboembolism after recent brain surgery: Evaluating the risk of intracranial hemorrhage.
de Melo Junior JO; Lodi Campos Melo MA; da Silva Lavradas LA; Ferreira Lopes PG; Luiz Ornelas II; de Barros PL; da Mata Pereira PJ; Niemeyer Filho P
Clin Neurol Neurosurg; 2020 Oct; 197():106202. PubMed ID: 32916398
[TBL] [Abstract][Full Text] [Related]
37. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
[TBL] [Abstract][Full Text] [Related]
38. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
Djulbegovic M; Lee AI; Chen K
J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
[TBL] [Abstract][Full Text] [Related]
39. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
40. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]